DLA Piper advises Insilico Medicine in Series A financing

DLA Piper represented Insilico Medicine Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research, on the completion of its Series A round of financing led by WuXi AppTec's Corporate Venture Fund.

The Series A investors also included Pavilion Capital, Juvenescence Limited and BOLD Capital. The strategic investment was conditional upon the successful experimental validation of Insilico Medicine's Generative Adversarial Networks (GAN) and Reinforcement Learning (RL)-based drug discovery pipeline and is intended to closely integrate the cutting-edge artificial intelligence of Insilico Medicine and strength of the laboratory infrastructure and expertise in medicinal chemistry of WuXi AppTec.

The DLA Piper team representing Insilico Medicine was led by partner Matthew Gorra (Baltimore), and also included associate Jay Buchanan (Austin).